Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Opportunities in Arthritis and Musculoskeletal Disorders – 2032
Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Opportunities in Arthritis and Musculoskeletal Disorders – 2032
The NSAIDs market encompasses medications like ibuprofen, naproxen, and diclofenac, widely used to alleviate pain, reduce inflammation, and lower fever. These drugs are available in various formats—oral pills, topical gels, and parenteral formulations—and can be purchased through hospital pharmacies, retail outlets, and online stores. The market is driven by rising incidence of chronic inflammatory conditions (such as arthritis and migraines), strong consumer preference for over-the-counter remedies over opioids, and advancements in safer formulations (like COX‑2 inhibitors and topical applications). Despite concerns over side effects such as gastrointestinal irritation and cardiovascular risks, demand continues to grow thanks to expanded distribution, improved treatment options, and increased healthcare access globally.
According to Fortune Business Insights, the global non-steroidal anti-inflammatory drugs (NSAIDs) market was valued at USD 15.58 billion in 2019 and is projected to reach USD 32.33 billion by 2032, exhibiting a CAGR of 5.8% during the forecast period. In 2019, North America dominated the NSAIDs market with a market share of 44.03%.
GlaxoSmithKline plc
Pfizer Inc.
Johnson & Johnson Services, Inc.
Bayer AG
AstraZeneca
Boehringer Ingelheim International GmbH
Zyla Life Sciences
Horizon Therapeutics plc
Others
In May 2019, Perrigo Company secured FDA approval for an Abbreviated New Drug Application (ANDA) referencing Voltaren Gel, marking a milestone in topical NSAID accessibility .
Chronic Pain Prevalence: Widespread conditions like arthritis, migraine, and ophthalmic disorders (e.g., post-surgery inflammation) push NSAIDs into the forefront. CDC data reveals over 50 million U.S. adults experience chronic pain, with 19.6 million suffering high-impact pain .
NSAIDs over Opioids: Growing recognition of opioid risks since late 2010s encourages safer, non-addictive NSAID use. Ibuprofen and naproxen are now primary line therapies per family physician guidelines .
Adverse Effects: NSAIDs are linked to gastrointestinal issues—ulcers, bleeding—often prompting emergency admissions in the U.S., which may deter long-term or high-dose usage .
Pharmaceutical firms are racing to develop selective COX‑2 inhibitors, aiming for targeted pain relief with fewer side-effects. Celebrex remains the only COX‑2 drug approved in the U.S. Pfizer's Celebrex, alongside experimental combinations like Crystal Genomics' CG100649 (COX‑2/CA inhibitor in Phase III), underscores the market's innovation focus .
Arthritis: Leading segment due to high rheumatoid and osteoarthritis rates, fueled by aging populations and topical NSAID adoption .
Migraine: Increasing NSAID use—especially Advil—for headache relief .
Ophthalmic Diseases: Used post-surgery to reduce inflammation and pain, driving growth .
Others: Treat common conditions like cramps, bursitis, ankylosing spondylitis, and atopic dermatitis—Pfizer's Eucrisa approval in 2016 exemplifies expansion into new indications .
Oral: Largest share, preferred for convenience—and driven by broader COX‑2 NSAID uptake like Celebrex .
Parenteral: Includes topical (e.g., Voltaren Gel) and injectable forms, anticipated to grow .
Hospital Pharmacies: Lead distribution due to high prescription rates and insurance support .
Retail Pharmacies: OTC ibuprofen, diclofenac, Voltaren, and new RX-to-OTC switches support retail growth—e.g. 2018's OTC ibuprofen capsule FDA approval .
Online Pharmacies: Poised for growth thanks to e-commerce adoption and convenience .
Dominates with a 44.03% market share and USD 6.86 billion in 2019. Driven by strong presence of key players, arthritis cases, and R&D activity .
Significant growth propelled by migraine prevalence, supportive reimbursement policies, and public health awareness .
Fastest-growing region due to increasing geriatric population, rising OTC NSAID adoption, and cost advantages over biologic alternatives .
GSK and Pfizer lead in revenue as of 2019. GSK’s market dominance is largely due to Voltaren Gel and its alliance with Pfizer’s Advil brand, while Pfizer’s Celebrex and diverse NSAID portfolio secure its second position.
Smaller and emerging companies are competing on innovation—development of COX‑2 inhibitors, topical formulations, insurance coverage strategies, and digital drug delivery methods.
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/non-steroidal-anti-inflammatory-drugs-nsaids-market-102823
The NSAID market is primed for continued expansion driven by:
📈 Demographic trends—aging populations increasing arthritis prevalence.
🚫 Opioid shift—demand for safer pain relief continues to favor NSAIDs.
🧪 New formulations—COX‑2 selective drugs, topical gels, combination products.
🌐 Access & affordability—OTC switches, online pharmacies, and insurance coverage.
🌍 Geographic expansion—growth in Asia-Pacific, Latin America, and the Middle East.
The NSAID market is on track to exceed USD 32.33 billion by 2032, driven by its indispensable role in managing pain and inflammation. Addressing safety concerns through innovation in drug design, distribution, and insurance will be critical. Leaders like GSK and Pfizer will continue shaping the space—but emerging players and next-gen NSAIDs offer promising future dynamics for investors, healthcare systems, and patients.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com